Preclinical CRO Focus ImQuest BioSciences operates as a preclinical contract research organization with expertise in virology, microbiology, oncology, and infectious disease drug development, suggesting opportunities to position end-to-end preclinical services for small molecules, biologics, vaccines, and antimicrobial therapies.

Diverse Platform Their ImQuest SUCCESS platform offers compound screening, mechanism of action analysis, and toxicity profiling, enabling potential cross-sell into target validation, pharmacology studies, and safety testing for clients advancing candidates through preclinical pipelines.

Small to Mid Market With 11-50 employees and revenue in the 10 to 25 million range, ImQuest sits in the small-to-mid market segment, presenting upsell opportunities to expand services, retainment programs, or longer-term retainer collaborations with mid-size pharma and biotech clients.

Historical Wins Awards and notable collaborations, such as recognition as a best place to work and past neuthropenic mouse infection model work, indicate credibility and demonstrated execution in infectious disease research, which can be leveraged in sales pitches to de-risk outsourcing decisions.

Expansion Potential Experience across HBV, HCV, influenza, and antimicrobial areas, plus partnerships in drug development and formulation R&D, point to opportunities to cross-sell additional services like formulation development, in vivo modeling, and translational pharmacology to existing or new clients pursuing infectious disease programs.